Kexing Biopharm's bevacizumab biosimilar wins approval in Bolivia

Kexing Biopharm (688136.SH) recently announced that its bevacizumab biosimilar product has received marketing approval from Bolivia's National Administration of Drugs and Health Technologies (AGEMED). This marks the fifth country approval for the bevacizumab product developed through Kexing Biopharm's collaboration with BioDlink.

Bevacizumab is a widely used oncology therapeutic, globally indicated for multiple cancers including metastatic colorectal cancer, advanced/metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer. It represents a blockbuster product in the oncology treatment landscape.

According to the China Chamber of Commerce for Import and Export of Medicines and Health Products, China's pharmaceutical exports to emerging markets including ASEAN, Latin America, and Africa showed steady growth in 2024, with exports to Latin America increasing by 11.4%. Latin America has consistently served as a key commercial region for Kexing Biopharm, and this approval in Bolivia will strengthen the foundation for deeper cultivation of this market.

Since the beginning of this year, Kexing Biopharm has secured marketing approvals for multiple products in different countries. The bevacizumab biosimilar has now gained regulatory approval in five countries, including Pakistan and Indonesia, with registration processes advancing rapidly in over twenty additional countries. Kexing Biopharm has established a subsidiary in Latin America and built a localized operations team in China, positioning the company to deeply develop this regional market and enhance patient access to medicines.